BIONDD
LIVE

Serial Number

79375208

Owner

Biograil ApS

Attorney

Olivia M. Clavio

Filing Date

Jun 21, 2023

Add to watchlist:

No watchlists yet
View on USPTO

BIONDD Trademark

Serial Number: 79375208 • Registration: 7876926

BIONDD is a trademark filed by Biograil ApS on June 21, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Biograil ApS (3 trademarks)

Langebjerg 1

Entity Type: 99

Trademark Details

Filing Date

June 21, 2023

Registration Date

August 5, 2025

Published for Opposition

June 17, 2025

Goods & Services

Medical apparatus and instruments for use in endovascular procedures; Drug delivery devices sold empty, in the nature of self-implanting endovascular spikes, contained within ingestible dissolvable capsules, for medical, dental or veterinary use; Ingestible devices for use in medical diagnosis and treatment, namely, capsule endoscopes for medical purposes

Ingestible drug delivery agents in the form of capsules filled with pharmaceutical preparations for the treatment of cardiovascular disease, cancerous diseases, joint diseases, infectious diseases, gastrointestinal diseases, ocular disorders and diseases, bacteria-based diseases and disorders, autoimmune diseases and disorders, kidney diseases and disorders, bone diseases, diabetes, blood disorders, pain, inflammation, sepsis, alopecia, obesity, cognitive disorders, respiratory diseases and disorders, and immune system related diseases and disorders

Scientific research for medical purposes; medical laboratory services; consultancy relating to product research and development in the field of ingestible devices; laboratory research services relating to oral delivery devices for pharmaceuticals that cannot be absorbed from an ordinary tablet or capsule; scientific research and product development; research and development of new products; clinical research in the field of pharmaceuticals; biological research and medical research; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; scientific laboratory services

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Mar 5, 2026 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Feb 13, 2026 FICS
FINAL DISPOSITION PROCESSED
Feb 13, 2026 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Nov 5, 2025 FICR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Aug 5, 2025 NRCC
REGISTERED-PRINCIPAL REGISTER
Aug 5, 2025 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 17, 2025 NPUB
PUBLISHED FOR OPPOSITION
Jun 17, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 11, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 13, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 12, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 12, 2025 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
May 12, 2025 ERSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
May 12, 2025 RCCK
CHANGE OF NAME/ADDRESS REC'D FROM IB
Mar 21, 2025 ADCH
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jan 10, 2025 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 25, 2024 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Dec 25, 2024 OPNR
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Oct 28, 2024 GNS3
LETTER OF SUSPENSION E-MAILED
Oct 28, 2024 GNSL
SUSPENSION LETTER WRITTEN
Oct 28, 2024 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 29, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 29, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 29, 2024 TROA
REFUSAL PROCESSED BY IB
Apr 23, 2024 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Mar 29, 2024 RFCS
REFUSAL PROCESSED BY MPU
Mar 29, 2024 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Mar 10, 2024 RFCR
NON-FINAL ACTION WRITTEN
Mar 9, 2024 CNRT
ASSIGNED TO EXAMINER
Mar 9, 2024 DOCK
APPLICATION FILING RECEIPT MAILED
Aug 1, 2023 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 28, 2023 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 27, 2023 REPR